Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B

November 12, 2026 updated by: Xiamen Amoytop Biotech Co., Ltd.

A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)

This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Beijing, China
        • Beijing Ditan Hospital, Capital Medical University
        • Contact:
          • Minghui Li
      • Xi'an, China
        • The Second Affiliated Hospital of Xi'an Jiaotong University
        • Contact:
          • Shuangsuo Dang
      • Xiamen, China
        • The First Affiliated Hospital of Xiamen University
        • Contact:
          • Xiulan Xue

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Voluntarily participate in this trial and sign the informed consent form;
  • Aged 18 to 65 years (inclusive), male or female;
  • Body mass index (BMI) between 18 and 32 kg/m² (inclusive);
  • HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening;
  • No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening;
  • HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements;
  • Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation.

Exclusion Criteria:

  • Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery;
  • Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection;
  • History of other liver diseases;
  • History of liver cirrhosis;
  • Imaging suggestive of a suspected malignant hepatic lesion;
  • Past or current evidence of hepatic decompensation;
  • History of extrahepatic diseases potentially associated with HBV immune status;
  • Other diseases associated with vasculitis;
  • Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening;
  • History of malignancy;
  • Prior solid organ or bone marrow transplantation;
  • Presence or history of severe psychiatric disorders;
  • Severe retinopathy or other serious ophthalmic diseases;
  • Prior or current use of prohibited medications;
  • Concomitant hematological diseases;
  • Abnormal laboratory findings;
  • Abnormal QTcF interval;
  • History of allergy;
  • Lactating female subjects or those with a positive serum pregnancy test at screening;
  • Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial;
  • Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 2

Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol

Once daily, orally, until the end of the trial

Experimental: Group 1

Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol

Once daily, orally, until the end of the trial

Experimental: Group 3

Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol

Once daily, orally, until the end of the trial

Experimental: Group 4

Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol

Once daily, orally, until the end of the trial

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)
Time Frame: throughout the full study period,an average of 38 weeks
throughout the full study period,an average of 38 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
HBsAg, HBsAb and HBV DNA levels and changes from baseline
Time Frame: throughout the full study period,an average of 38 weeks
throughout the full study period,an average of 38 weeks
HBsAg seroclearance rate
Time Frame: throughout the full study period,an average of 38 weeks
throughout the full study period,an average of 38 weeks
HBsAg seroconversion rate
Time Frame: throughout the full study period,an average of 38 weeks
throughout the full study period,an average of 38 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Minghui Li, Ph.D, Beijing Ditan Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 31, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ACT201-4-1-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe